These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 18571811)
1. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Seimiya M; Tomonaga T; Matsushita K; Sunaga M; Oh-Ishi M; Kodera Y; Maeda T; Takano S; Togawa A; Yoshitomi H; Otsuka M; Yamamoto M; Nakano M; Miyazaki M; Nomura F Hepatology; 2008 Aug; 48(2):519-30. PubMed ID: 18571811 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Di Tommaso L; Destro A; Fabbris V; Spagnuolo G; Laura Fracanzani A; Fargion S; Maggioni M; Patriarca C; Maria Macchi R; Quagliuolo M; Borzio M; Iavarone M; Sangiovanni A; Colombo M; Roncalli M Hepatology; 2011 May; 53(5):1549-57. PubMed ID: 21520170 [TBL] [Abstract][Full Text] [Related]
3. Formiminotransferase Cyclodeaminase Suppresses Hepatocellular Carcinoma by Modulating Cell Apoptosis, DNA Damage, and Phosphatidylinositol 3-Kinases (PI3K)/Akt Signaling Pathway. Chen J; Chen Z; Huang Z; Yu H; Li Y; Huang W Med Sci Monit; 2019 Jun; 25():4474-4484. PubMed ID: 31203308 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions. Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547 [TBL] [Abstract][Full Text] [Related]
5. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Nassar A; Cohen C; Siddiqui MT Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109 [TBL] [Abstract][Full Text] [Related]
6. A triple stain of reticulin, glypican-3, and glutamine synthetase: a useful aid in the diagnosis of liver lesions. Swanson BJ; Yearsley MM; Marsh W; Frankel WL Arch Pathol Lab Med; 2015 Apr; 139(4):537-42. PubMed ID: 25822763 [TBL] [Abstract][Full Text] [Related]
7. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions. Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368 [TBL] [Abstract][Full Text] [Related]
8. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409 [TBL] [Abstract][Full Text] [Related]
9. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis]. Tátrai P Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466 [TBL] [Abstract][Full Text] [Related]
10. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006 [TBL] [Abstract][Full Text] [Related]
11. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806 [TBL] [Abstract][Full Text] [Related]
12. Using a yeast two-hybrid system to identify FTCD as a new regulator for HIF-1α in HepG2 cells. Yu Z; Ge Y; Xie L; Zhang T; Huang L; Zhao X; Liu J; Huang G Cell Signal; 2014 Jul; 26(7):1560-6. PubMed ID: 24686083 [TBL] [Abstract][Full Text] [Related]
13. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology. McKnight R; Nassar A; Cohen C; Siddiqui MT Cancer Cytopathol; 2012 Aug; 120(4):223-9. PubMed ID: 22298472 [TBL] [Abstract][Full Text] [Related]
14. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and glypican-3 in fine-needle aspiration biopsies. Fujiwara M; Kwok S; Yano H; Pai RK Cancer Cytopathol; 2012 Aug; 120(4):230-7. PubMed ID: 22434791 [TBL] [Abstract][Full Text] [Related]
15. The loss of phenol sulfotransferase 1 in hepatocellular carcinogenesis. Yeo M; Na YM; Kim DK; Kim YB; Wang HJ; Lee JA; Cheong JY; Lee KJ; Paik YK; Cho SW Proteomics; 2010 Jan; 10(2):266-76. PubMed ID: 19904771 [TBL] [Abstract][Full Text] [Related]
16. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma]. Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223 [TBL] [Abstract][Full Text] [Related]
17. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Lagana SM; Salomao M; Bao F; Moreira RK; Lefkowitch JH; Remotti HE Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):170-6. PubMed ID: 22914605 [TBL] [Abstract][Full Text] [Related]
18. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081 [TBL] [Abstract][Full Text] [Related]
19. Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Yu CY; Lu FJ; Chow LP J Proteome Res; 2005; 4(6):2062-9. PubMed ID: 16335951 [TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers. Witjes CD; ten Kate FJ; Verhoef C; de Man RA; IJzermans JN J Clin Pathol; 2013 Aug; 66(8):687-91. PubMed ID: 23585667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]